

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/597,304
				Filing Date	July 19, 2006
				First Named Inventor	John P. Morseman
				Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	1	of	1	Attorney Docket Number	2997-74-PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. <sup>1</sup>	
	1	COSTA, E. et al., "Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability," Neurobiology of Disease, Blackwell Scientific Publications, Oxford, GB, Vol. 8, No. 5, Oct. 1, 2001, pp. 723-742
	2	PEET MALCOLM, "Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical trial results," Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 69, No. 6, Dec. 2003, pp. 477-485

Examiner Signature	/Jennifer Kim/	Date Considered	08/11/2010
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.K./